Personalized Treatment

My mother has just been diagnosed with ovarian cancer. Her doctors say her outlook is poor, but I have read that some newly available chemotherapy drugs could benefit her more. Is there a way of finding out if this is the case?

Regular Process

The choice of optimal cancer treatment remains one of the great challenges in oncology. Almost a fifth of ovarian cancer cases are associated with mutations in genes called BRCA1 or BRCA2. These women particularly benefit from targeted (so-called ‘PARP inhibitor’) therapy, which greatly improves survival rates. Sometimes, even if these patients undergo testing for mutations in these genes, doctors do not always manage to choose the best therapy. This is often due to tumor-specific characteristics, which are not obvious to histopathology doctors.

  • Visual/Process/Subsite/26Created with Sketch.
    01
    Identified tumor cell
  • Visual/Process/Subsite/27Created with Sketch.
    02
    Genetic material extracted from tumor
  • Visual/Process/Subsite/04Created with Sketch.
    03
    Report about genetic abnormalities
  • Visual/Process/Subsite/09Created with Sketch.
    04
    Tailor treatment

4D Path Process

4D Path is developing solutions based on analysis of the tumor image that bypass the need for genetic testing and help doctors to choose the most effective cancer treatment.

Automated
  • Visual/Process/Subsite/26Created with Sketch.
    01
    Identified tumor cells
  • Visual/Process/Subsite/28Created with Sketch.
    02
    Automated finding morphological features
  • Visual/Process/Subsite/04Created with Sketch.
    03
    Report about genetic abnormalities
  • Visual/Process/Subsite/09Created with Sketch.
    04
    Tailor treatment
Personalized therapy and prediction of drug response remain at the heart of future developments in oncology. An example is ovarian cancer: some women have tumors that carry BRCA1 or BRCA2 gene mutations (germline or acquired). These patients can benefit from targeted poly (ADP-ribose) polymerase (PARP) inhibitor therapy, which can improve survival rates and is well tolerated. Yet, there are women whose tumors have no such mutations who may also benefit while others unexpectedly respond poorly to therapy, likely as a result of epigenetic changes within the tumor and its microenvironment. Analogous permutations of this scenario also occur across a range of other malignancies. 4D Path is developing algorithm-based strategies using tumor image data and treatment response data from historical cases in order to stratify patients according to available therapies, which will contribute meaningfully to the choice of the most efficacious treatment.